• T C Harding, K E Koprivnikar, G H Tu, N Zayek, S Lew, A Subramanian, A Sivakumaran, D Frey, K Ho, M J VanRoey, T C Nichols, D A Bellinger, S Yendluri, J Waugh, J McArthur, G Veres, and B A Donahue.
• Cell Genesys Inc., South San Francisco, CA 94080, USA.
• Gene Ther. 2004 Jan 1; 11 (2): 204-13.

AbstractPrevious experiments have demonstrated the stable expression of factor IX (FIX) protein in mice and canine models of hemophilia B following portal vein gene transfer with a recombinant adeno-associated virus (rAAV) vector encoding FIX. Here, we present the results of studies that further optimized the rAAV vector transgene cassette used to express FIX and explored the use of the less-invasive intravenous (i.v.) route of vector administration for the treatment of hemophilia B. First, a liver-specific promoter was evaluated in conjunction with cis-acting regulatory elements in mice. Constructs that included both the beta-globin intron and the woodchuck hepatitis virus post-transcriptional regulatory element resulted in the highest level of FIX expression in vivo. Using this optimized vector, we demonstrate that i.v. injection was feasible for hepatic gene transfer in mice, achieving 70-80% of portal vein expression levels of FIX. In further studies using the Chapel Hill strain of hemophilia B dogs, we demonstrate for the first time FIX expression and partial correction of the bleeding disorder following i.v. administration of an AAV vector.

29 keywords...

hide…